Allogene Therapeutics Inc. 计划将此次融资的净收益主要用于公司一般运营需求。这些资金将支持多项核心业务活动,其中重点包括推进临床试验项目及持续投入研发工作。此举旨在加速公司创新疗法的开发进程,强化其在细胞治疗领域的技术优势。
Allogene Therapeutics Inc. 计划将此次融资的净收益主要用于公司一般运营需求。这些资金将支持多项核心业务活动,其中重点包括推进临床试验项目及持续投入研发工作。此举旨在加速公司创新疗法的开发进程,强化其在细胞治疗领域的技术优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.